PL2402325T3 - Hydroksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT - Google Patents

Hydroksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT

Info

Publication number
PL2402325T3
PL2402325T3 PL11166125T PL11166125T PL2402325T3 PL 2402325 T3 PL2402325 T3 PL 2402325T3 PL 11166125 T PL11166125 T PL 11166125T PL 11166125 T PL11166125 T PL 11166125T PL 2402325 T3 PL2402325 T3 PL 2402325T3
Authority
PL
Poland
Prior art keywords
pyrimidines
protein kinase
kinase inhibitors
akt protein
cyclopenta
Prior art date
Application number
PL11166125T
Other languages
English (en)
Polish (pl)
Inventor
Ian S Mitchell
James F Blake
Rui Xu
Nicholas C Kallan
Dengming Xiao
Keith Lee Spencer
Josef R Bencsik
Jun Liang
Brian Safina
Birong Zhang
Christine Chabot
Steven Do
Eli W Wallace
Anna L Banka
Stephen T Schlachter
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2402325(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of PL2402325T3 publication Critical patent/PL2402325T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
PL11166125T 2006-07-06 2007-07-05 Hydroksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT PL2402325T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
EP11166125.2A EP2402325B1 (en) 2006-07-06 2007-07-05 Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
EP07799337A EP2049501B1 (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2402325T3 true PL2402325T3 (pl) 2016-01-29

Family

ID=38686743

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11166125T PL2402325T3 (pl) 2006-07-06 2007-07-05 Hydroksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT
PL07799337T PL2049501T3 (pl) 2006-07-06 2007-07-05 Hydroksylowane i metoksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07799337T PL2049501T3 (pl) 2006-07-06 2007-07-05 Hydroksylowane i metoksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT

Country Status (34)

Country Link
EP (4) EP2402325B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP5266216B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (5) KR20140093291A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN102816124A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR061842A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE524447T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2007269060B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (3) BRPI0713923B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2656622C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2007001993A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO6150161A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR10600A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1112117T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2049501T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2372774T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20110908T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE026237T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL196028A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014KN02886A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA31655B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (4) MX2008016202A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY147364A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO342346B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (3) NZ610633A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2402325T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2049501E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS52212B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2478632C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (4) SG185980A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2402325T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW201332994A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA95641C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2008006040A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200900070B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054418B1 (en) * 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
JP5268904B2 (ja) 2006-07-06 2013-08-21 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼ阻害剤としてのシクロペンタ［ｄ］ピリミジン
WO2008006025A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20110135569A1 (en) 2007-03-20 2011-06-09 Peak Biosciences Inc. Method for therapeutic administration of radionucleosides
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
EP2404907B1 (en) 2007-07-05 2015-01-14 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MX2010007546A (es) * 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
WO2009089454A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CA2711782C (en) * 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
EP2247578B1 (en) * 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
WO2012087336A1 (en) * 2010-12-23 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
AU2012236138A1 (en) 2011-04-01 2013-11-14 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
JP6293655B2 (ja) * 2011-04-01 2018-03-14 ジェネンテック， インコーポレイテッド 癌治療に対する感受性を予測するためのバイオマーカー
CA2831932A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt and mek inhibitor compounds, and methods of use
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
BR112014028585B1 (pt) * 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
MX2014013865A (es) * 2012-05-17 2015-05-07 Genentech Inc Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada.
MY169028A (en) 2012-05-17 2019-02-04 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
KR20210095238A (ko) * 2012-05-17 2021-07-30 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2928488A1 (en) * 2012-12-07 2015-10-14 The General Hospital Corporation Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP6340162B2 (ja) * 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
EP3068770B1 (en) * 2013-11-15 2019-10-23 F.Hoffmann-La Roche Ag Processes for the preparation of pyrimidinylcyclopentane compounds
MX380718B (es) * 2014-09-26 2025-03-12 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
EP4613333A2 (en) 2016-08-10 2025-09-10 F. Hoffmann-La Roche AG Pharmaceutical compositions comprising akt protein kinase inhibitors
AU2017348322B8 (en) 2016-10-28 2021-12-23 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating EZH2-mediated cancer
AU2019231689A1 (en) * 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
AU2019288740A1 (en) 2018-06-21 2021-01-14 Icahn School Of Medicine At Mount Sinai WD40 repeat domain protein 5 (WDR5) degradation / disruption compounds and methods of use
WO2020131765A1 (en) 2018-12-19 2020-06-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
AU2020214258B2 (en) 2019-01-29 2025-08-28 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
EP3946330A1 (en) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
WO2020210337A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
EP4122922A4 (en) * 2020-03-17 2023-08-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. CONDENSED BICYCLIC DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND PHARMACEUTICAL USE THEREOF
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP7607057B2 (ja) 2020-06-16 2024-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヒドロキシル化シクロペンチルピリミジン化合物を製造するための方法
CA3186568A1 (en) 2020-07-22 2022-01-27 Changyou MA Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
KR20240168418A (ko) 2022-03-31 2024-11-29 아스트라제네카 아베 암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
AU2023362285A1 (en) 2022-10-17 2025-05-29 Astrazeneca Ab Combinations of a serd for the treatment of cancer
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
TW202444900A (zh) 2023-01-31 2024-11-16 瑞士商赫孚孟拉羅股份公司 具有增加的酮還原酶活性的突變型酮還原酶以及涉及其的方法及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP3297058B2 (ja) * 1997-01-08 2002-07-02 エフ．ホフマン−ラ ロシュ アーゲー 三環式ベンゾ［ｅ］イソインドール及びベンゾ［ｈ］イソキノリン
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
NZ524461A (en) * 2000-08-18 2004-12-24 Millennium Pharm Inc Quinazoline derivatives as kinase inhibitors
MXPA03002291A (es) * 2000-09-15 2003-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1383463B1 (en) * 2001-03-30 2011-04-27 King Pharmaceuticals, Inc. Fused thiophene compounds and use thereof in the treatment of chronic pain
EP1551812B1 (en) * 2001-12-06 2009-03-04 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
CN102786482A (zh) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
ATE464303T1 (de) * 2004-04-28 2010-04-15 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
JP5268904B2 (ja) * 2006-07-06 2013-08-21 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼ阻害剤としてのシクロペンタ［ｄ］ピリミジン
EP2054418B1 (en) * 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

Also Published As

Publication number Publication date
KR101495408B1 (ko) 2015-02-25
RU2012155606A (ru) 2014-06-27
NZ610633A (en) 2014-12-24
TW200817373A (en) 2008-04-16
SG188905A1 (en) 2013-04-30
KR20140093291A (ko) 2014-07-25
JP2013091670A (ja) 2013-05-16
IL196028A0 (en) 2009-09-01
KR20150051240A (ko) 2015-05-11
BR122013028012B1 (pt) 2021-04-06
TWI402266B (zh) 2013-07-21
NO20090581L (no) 2009-04-06
DK2402325T3 (en) 2015-12-07
KR20090030333A (ko) 2009-03-24
CN101578273B (zh) 2012-11-14
NZ573732A (en) 2012-03-30
EP2402325A3 (en) 2012-06-13
EP2049501B1 (en) 2011-09-14
MX366319B (es) 2019-07-05
EP2966065A2 (en) 2016-01-13
BR122013028005B1 (pt) 2021-04-06
JP2014231530A (ja) 2014-12-11
KR20130029364A (ko) 2013-03-22
RU2009103900A (ru) 2010-08-20
RS52212B (en) 2012-10-31
ZA200900070B (en) 2010-03-31
KR101178672B1 (ko) 2012-09-07
JP2009542723A (ja) 2009-12-03
MX377920B (es) 2025-03-11
BRPI0713923A2 (pt) 2013-07-02
ES2554228T3 (es) 2015-12-17
TW201332994A (zh) 2013-08-16
AU2007269060B2 (en) 2014-02-20
IL241705A0 (en) 2015-11-30
NO342346B1 (no) 2018-05-07
EP2399909A1 (en) 2011-12-28
HUE026237T2 (en) 2016-06-28
MA31655B1 (fr) 2010-09-01
DK2049501T3 (da) 2011-12-12
SI2402325T1 (sl) 2015-12-31
AR109424A2 (es) 2018-11-28
KR101578877B1 (ko) 2016-02-22
CA2656622A1 (en) 2008-01-10
AR061842A1 (es) 2008-09-24
IL196028A (en) 2017-02-28
HK1160134A1 (en) 2012-08-10
CR10600A (es) 2009-02-20
BRPI0713923B1 (pt) 2020-09-29
AR093810A2 (es) 2015-06-24
ES2554252T3 (es) 2015-12-17
EP2399909B1 (en) 2015-08-26
BRPI0713923B8 (pt) 2021-05-25
HK1126768A1 (en) 2009-09-11
SG184706A1 (en) 2012-10-30
UA95641C2 (xx) 2011-08-25
PL2049501T3 (pl) 2012-02-29
AU2007269060A1 (en) 2008-01-10
CN102816124A (zh) 2012-12-12
PT2049501E (pt) 2011-12-30
MX337843B (es) 2016-03-22
CO6150161A2 (es) 2010-04-20
SI2049501T1 (sl) 2012-01-31
CY1112117T1 (el) 2015-11-04
CN101578273A (zh) 2009-11-11
CA2836316A1 (en) 2008-01-10
JP5266216B2 (ja) 2013-08-21
ES2372774T3 (es) 2012-01-26
SG10201802127UA (en) 2018-04-27
EP2402325A2 (en) 2012-01-04
HK1160638A1 (en) 2012-08-10
NZ597647A (en) 2013-08-30
EP2049501A1 (en) 2009-04-22
MY147364A (en) 2012-11-30
EP2402325B1 (en) 2015-08-26
JP5836294B2 (ja) 2015-12-24
BR122013028012B8 (pt) 2021-05-25
RU2478632C2 (ru) 2013-04-10
SG185980A1 (en) 2012-12-28
MX2019008117A (es) 2019-09-04
CA2656622C (en) 2017-09-12
MX2008016202A (es) 2009-02-11
KR20130141717A (ko) 2013-12-26
WO2008006040A1 (en) 2008-01-10
BR122013028005B8 (pt) 2021-05-25
JP2013177470A (ja) 2013-09-09
IN2014KN02886A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-08
HRP20110908T1 (hr) 2012-02-29
EP2966065A3 (en) 2016-03-02
ATE524447T1 (de) 2011-09-15
CL2007001993A1 (es) 2008-06-20

Similar Documents

Publication Publication Date Title
PL2402325T3 (pl) Hydroksylowane cyklopenta[d]pirymidyny jako inhibitory kinazy białkowej AKT
IL196051A0 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
EP2497470B8 (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
IL195238A0 (en) Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
EP2240483B8 (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
ZA200806313B (en) Pyrrolo [3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors
AU2005310968A1 (en) Bicyclic amides as kinase inhibitors
PL2205603T3 (pl) Pochodne pirymidyny jako inhibitory kinaz białkowych
IL195005A0 (en) Inhibitors of akt (protein kinase b)
ZA200904236B (en) 2 substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors
IL206607A0 (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
ZA201004769B (en) Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
IL194625A0 (en) Substituted 3-cyanopyridines as protein kinase inhibitors
ZA200809545B (en) Inhibitors of Akt (protein kinase B)
HK1122021A (en) Imidazopyrazines as protein kinase inhibitors
HK1127060A (en) Imidazopyrazines as protein kinase inhibitors
HK1139147A (en) Imidazopyrazines as protein kinase inhibitors
AU2014201698B2 (en) Means for inhibiting the expression of protein kinase 3
HK1134814A (en) Benzofuropyrimidinones as protein kinase inhibitors
HK1120508A (en) Kinase inhibitors
HK1090927A (en) Pyrazolotriazines as kinase inhibitors
HK1126763A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1126764A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1126765A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
HK1126497A (en) Inhibitors of akt (protein kinase b)